SG Americas Securities
ADCT icon

SG Americas Securities’s ADC Therapeutics ADCT Stock Holding History

SG Americas Securities’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,448
Closed -$86K – 3173
2025
Q4 		$86K Buy
+24,448
New +$99.2K ﹤0.01% 3265
2025
Q2 		– Sell
-23,878
Closed -$34K – 2885
2025
Q1 		$34K Sell
23,878
-12,262
-34% -$20.8K ﹤0.01% 3314
2024
Q4 		$72K Buy
36,140
+9,483
+36% +$24.8K ﹤0.01% 2829
2024
Q3 		$84K Buy
+26,657
New +$84.1K ﹤0.01% 3122
2021
Q2 		– Sell
-5,000
Closed -$122K – 2816
2021
Q1 		$122K Buy
+5,000
New +$145K ﹤0.01% 2974

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SG Americas Securities's ADCT Position: Q1 2026 in Review

SG Americas Securities sold out of ADC Therapeutics (ADCT) in Q1 2026, closing a stake of 24,448 shares — an estimated $86K sold.

SG Americas Securities first reported a position in ADCT in Q1 2021 and held it in 5 quarters. The position peaked at $122K in Q1 2021. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • SG Americas Securities reported no remaining ADC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SG Americas Securities sold 24,448 ADC Therapeutics shares in Q1 2026, an estimated $86K.
  • SG Americas Securities first reported a position in ADC Therapeutics in Q1 2021 and held it in 5 quarters.
  • SG Americas Securities's ADC Therapeutics position peaked at $122K in Q1 2021.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.